Total Synthesis of Pyrano[3,2-*e*]indole Alkaloid Fontanesine B by Double Cyclization Strategy

Tomoki Itoh, Yuusuke Chiba, Shunsuke Kawaguchi, Yuki Koitaya, Yuuma Yoneta, Koji Yamada and Takumi Abe*

Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-tobetsu, Hokkaido 0610293, Japan

E-mail: <u>abe-t@hoku-iryo-u.ac.jp</u>

SUPPORTING INFORMATION

Contents	
1. General Experimental	S2
2. Experimental Procedure	S2-7
3. Copies of 'H and 'C NMR spectra	\$7–33

Experimental Section

1. General Experimental

Melting points were recorded with a Yanaco MP3 and are uncorrected. High-resolution MS spectra were recorded with a JEOL JMS-T100LP mass spectrometers. IR spectra were measured with a Shimadzu IRAffinity-1 spectrometer. The NMR experiments were performed with a JEOL JNM-ECA500 (500 MHz) spectrometer, and chemical shifts are expressed in ppm (δ) using residual undeuterated solvent as an internal reference. The following abbreviations were used to explain NMR peak multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet. Flash column chromatography was performed on silica gel (Silica Gel 60N, Kanto Chemical Co., Ltd.).

2. Experimental Procedure

General Procedure for the Synthesis of 4

A mixture of serotonin hydrochloride (2.55 g, 12 mmol) and aldehyde (10.0 mmol) in MeOH (150 mL) was stirred at room temperature for 0.5 h. Then to the mixture was added sodium cyanoborohydride (943 mg, 15 mmol) and stirred at room temperature for 1.5 h until the complete disappearance of starting material as indicated by TLC. After MeOH was removed by evaporation, saturated NaHCO₂ (150 mL) and AcOEt (150 mL) were added the residue. The whole was extracted with AcOEt (3 x 200 mL), washed with brine (2 x 150 mL). The organic layer was dried over MgSO₂ and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (CHCl./MeOH/Et.N = 100/10/1) to give **4**.



3-(2-Benzylaminoethyl)-1H-indol-5-ol (4a).

1.52 g, 57%: Pale yellow oil: IR (CHCl₃): 3296 cm⁻¹; ¹H-NMR (500 MHz, CD₃OD): δ 9.91 (br s, 1H), 7.20-7.23 (m, 2H), 7.13-7,18 (m, 4H), 6.92 (s, 1H), 6.91 (d, J = 2.3 Hz, 1H), 6.67 (dd, J = 2.3, 8.6 Hz, 1H), 3.66 (s, 2H), 3.33 (br s, 1H), 2.79-2.87 (m, 4H); ¹⁰C-NMR (125 MHz, CD₃OD): δ 149.9, 139.0, 131.9, 128.2, 128.0, 126.9, 123.0, 111.5, 111.3, 111.2, 102.3, 52.9, 48.8, 24.7 (three carbons are overlapped); HRMS (ESI): calcd for C₁₀H₁₀N₂O [M+H]⁺ 267.1497, found 267.1497.



3-[2-(4-methoxybenzylaminoethyl)]-1*H*-indol-5-ol (4b).

1.54 g, 52%: Colorless powder: mp 138—139 °C; IR (CHCl₃): 3481 cm⁻¹; ¹H-NMR (500 MHz, CD₂OD): δ 7.13-7.15 (m, 3H), 6.96 (s, 1H), 6.87 (d, *J* = 2.3 Hz, 1H), 6.80-6.82 (m, 2H), 6.65 (dd, *J* = 2.3, 8.6 Hz, 1H), 3.72 (s, 2H), 3.70

(br s, 1H), 3.33 (s, 3H), 2.88 (s, 4H); ^hC-NMR (125 MHz, CD₂OD): δ 159.3, 149.9, 131.9, 129.9, 129.6, 127.9, 123.0, 113.6, 111.4, 111.2, 110.8, 102.2, 54.3, 52.1, 48.4, 24.4 (two carbons are overlapped); HRMS (ESI): calcd for C_hH₂N₂O₂ [M+H]⁺ 297.1603, found 297.1604.



3-[2-(2,4-Dimethoxybenzylamino)ethyl]-1H-indol-5-ol (4c).

1.50 g, 46%: Colorless powder: mp 139—140 °C;: IR (CHCL): 3479 cm⁻⁺; ⁺H-NMR (500 MHz, CD₂OD): δ 7.19 (t, J = 8.6 Hz, 2H), 7.09 (s, 1H), 6.85 (s, 1H), 6.70 (dd, J = 2.3, 8.6 Hz, 1H), 6.48 (dd, J = 2.3, 8.6 Hz, 1H), 6.44 (s, 1H), 4.05 (s, 2H), 3.75 (s, 3H), 3.61 (s, 3H), 3.18 (t, J = 6.9 Hz, 2H), 3.06 (t, J = 7.4 Hz, 2H); ⁺C-NMR (125 MHz, CD₂OD): δ 162.7, 158.9, 150.3, 132.2, 131.9, 127.4, 124.0, 111.8, 111.6, 110.9, 107.8, 104.9, 101.9, 97.9, 54.7, 54.6, 46.7, 46.5, 21.9; HRMS (ESI): calcd for C₁H₂N₂O₂ [M+H]⁺ 313.1552, found 313.1553.

General Procedure for the C4 Pictet-Spengler/Allylic Transposition

A mixture of **4** (5 mmol) and 3-methyl-2-butenal (0.72 mL, 7.5 mmol) in 2-propanol/Et₃N (40 mL, v/v = 1/1) was heated under reflux with stirring until the complete disappearance of starting material as indicated by TLC. The mixture was cooled to rt. After addition of H₂O (80 mL), the whole was extracted with AcOEt (3 x 150 mL), washed with brine (2 x 100 mL). The organic layer was dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (AcOEt/hexane/Et₄N = 50/10/1) to give **8**.



N-Benzyl-2-(7,7-dimethyl-3,7-dihydropyrano[3,2-*e*]indol-1-yl)ethan-1-amine (8a).

1.3 g, 78%: Colorless powder: mp 110—112 °C; IR (CHCl₃): 3481 cm⁻¹; ¹H-NMR (500 MHz, CD₃OD): δ 7.17-7.24 (m, 5H), 7.05 (d, *J* = 8.6 Hz, 1H), 6.94 (s, 1H), 6.86 (d, *J* = 10.3 Hz, 1H), 6.56 (d, *J* = 8.6 Hz, 1H), 5.56 (d, *J* = 8.6 Hz, 1H), 3.75 (s, 3H), 3.69 (s, 2H), 2.98 (t, *J* = 7.5 Hz, 2H), 2.81 (t, *J* = 6.9 Hz, 2H), 1.34 (s, 6H); ¹⁰C-NMR (125 MHz, CD₃OD): δ 146.1, 139.1, 133.1, 129.0, 128.2, 126.9, 124.1, 122.5, 120.2, 112.5, 112.1, 111.8, 111.2, 74.5, 52.9, 49.3, 26.8, 26.1 (four carbons are overlapped); HRMS (ESI): calcd for C₂₁H₂₁N₂O [M+H]¹ 333.1967, found 333.1967.



2-(7,7-Dimethyl-3,7-dihydropyrano[3,2-e]indol-1-yl)-N-(4-methoxybenzyl)ethan-1-amine (8b).

890 mg, 60%: Colorless powder: mp 97–100 °C; IR (CHCl₃): 3481 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃): δ 7.92 (br s, 1H), 7.20 (d, *J* = 9.2 Hz, 2H), 7.07 (d, *J* = 9.2 Hz, 1H), 6.94 (d, *J* = 2.3 Hz, 1H), 6.90 (d, *J* = 10.3 Hz, 1H), 6.83 (d, *J* = 8.6 Hz, 2H), 6.71 (d, *J* = 8.6 Hz, 1H), 5.60 (d, *J* = 9.8 Hz, 1H), 3.78 (s, 3H), 3.76 (s, 2H), 3.05 (t, *J* = 6.9 Hz, 2H), 2.95 (t, *J* = 6.9 Hz, 2H), 1.43 (s, 6H); ¹⁰C-NMR (125 MHz, CDCl₃): δ 158.7, 146.8, 132.6, 129.7, 129.4, 123.7, 122.9, 120.3, 114.0, 113.9, 113.2, 112.9, 111.3, 74.9, 55.4, 53.4, 49.7, 27.9, 27.3 (four carbons are overlapped); HRMS (ESI): calcd for C₃H₃N₃O₃ [M+H]¹ 363.2073, found 363.2070.



N-(2,4-Dimethoxybenzyl)-2-(7,7-dimethyl-3,7-dihydropyrano[3,2-*e*]indol-1-yl)ethan-1-amine (8c).

911 mg, 46%: Colorless powder: mp 54—56 °C; IR (CHCl₃): 3479, 3309, 1732, 1614, 1589 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃): δ 8.24 (br s, 1H), 7.08 (d, J = 9.2 Hz, 1H), 7.04 (d, J = 9.2 Hz, 1H), 6.90 (s, 1H), 6.88 (d, J = 10.3 Hz, 1H), 6.69 (d, J = 8.6 Hz, 1H), 6.37-6.39 (m, 2H), 5.57 (d, J = 9.7 Hz, 1H), 3.77 (s, 3H), 3.76 (s, 3H), 3.65 (s, 2H), 3.05 (t, J = 7.2 Hz, 2H), 2.92 (t, J = 6.6 Hz, 2H), 2.10 (br s, 1H), 1.43 (s, 6H); ¹³C-NMR (125 MHz, CDCl₃): δ 160.2, 158.7, 146.7, 132.7, 130.5, 129.6, 123.9, 122.9, 120.6, 120.3, 113.8, 113.2, 112.8, 11.3, 103.7, 98.6, 74.9, 55.4, 55.2, 27.8, 27.3 (one carbon is overlapped); HRMS (ESI): calcd for C₂₄H₂₉N₂O₃ [M+H]+ 393.2178, found 393.2178.

General Procedure for the Carbonylative Cyclization of 8 using Triphosgene, Et.N and HBr

Triphosgene (149 mg, 0.5 mmol) was added to a mixture of **8** (1 mmol) and Et₃N (0.35 mL, 2.5 mmol) in toluene (100 mL) at room temperature and the mixture was heated at 70 °C with stirring for 0.5 h. After cooling to room temperature, HBr (30% in acetic acid, 0.3 mL) was added to the mixture and heated under reflux for 0.5 h. After cooling to room temperature and addition of H₄O (30 mL), the whole was extracted with AcOEt (3 x 70 mL), washed with brine (2 x 50 mL). The organic layer was dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (AcOEt/hexane = 3/1) to give **9** and **12**.



9-Benzyl-3,3-dimethyl-7,9,10,11-tetrahydropyrano[3,2-*e*]pyrido[3,4-*b*]indol-8(3*H*)-one (9a).

18 mg, 5%: Colorless powder: mp 254—257 °C; IR (CHCl₃): 3460, 1641 cm⁻¹; ¹H-NMR (500 MHz, DMSO-*d*₆): δ 11.50 (br s, 1H), 7.29-7.34 (m, 4H), 7.24 (t, *J* = 6.9 Hz, 1H), 7.12 (d, *J* = 8.6 Hz, 1H), 6.75 (d, *J* = 9.8 Hz, 1H), 6.68 (d, J = 8.6 Hz, 1H), 5.67 (d, J = 9.8 Hz, 1H), 4.66 (s, 2H), 3.54 (t, J = 6.9 Hz, 2H), 3.08 (t, J = 6.9 Hz, 2H), 1.33 (s, 6H); "C-NMR (125 MHz, DMSO- d_s): δ 161.0, 146.6, 138.5, 133.7, 130.4, 129.1, 128.4, 128.1, 127.7, 121.4, 119.8, 116.7, 115.5, 113.3, 113.2, 75.5, 49.1, 47.6, 27.5, 22.5 (three carbons are overlapped); HRMS (ESI): calcd for C_aH_aN_aO_a [M+H]⁺ 359.1760, found 359.1760.



9-(4-Methoxybenzyl)-3,3-dimethyl-7,9,10,11-tetrahydropyrano[3,2-e]pyrido[3,4-b]indol-8(3H)-one (9b).

24 mg, 6%: Colorless powder: mp 186—187 °C; IR (CHCl₃): 3462, 1638 cm⁻¹; 'H-NMR (500 MHz, CDCl₃): δ 9.42 (br s, 1H), 7.28 (d, *J* = 8.6 Hz, 2H), 7.17 (d, *J* = 9.2 Hz, 1H), 6.86 (d, *J* = 9.2 Hz, 2H), 6.80 (d, *J* = 9.2 Hz, 1H), 6.73 (d, *J* = 9.7 Hz, 1H), 5.60 (d, *J* = 9.7 Hz, 1H), 4.72 (s, 2H), 3.80 (s, 3H), 3.60 (t, *J* = 7.2 Hz, 2H), 3.14 (t, *J* = 7.5 Hz, 2H), 1.43 (s, 6H); "C-NMR (125 MHz, CDCl₃): δ 161.3, 159.1, 147.1, 133.2, 130.1, 129.6, 129.4, 128.0, 121.6, 119.6, 116.9, 116.1, 114.1, 113.6, 112.5, 75.5, 55.4, 48.9, 47.1, 27.3, 22.8 (three carbons are overlapped); HRMS (ESI): calcd for C₃₄H₂N₂O₃ [M+H]⁺ 389.1865, found 389.1868.



9-(2,4-Dimethoxybenzyl)-3,3-dimethyl-7,9,10,11-tetrahydropyrano[**3,2**-*e*]**pyrido**[**3,4**-*b*]**indol-8(***3H***)-one (9c).** 8 mg, 2%: Colorless powder: mp 209—211 °C; IR (CHCl₃): 3460, 1719, 1687, 1638, 1614 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃): δ 9.86 (br s, 1H), 7.27 (d, *J* = 8.0 Hz, 1H), 7.15 (d, *J* = 9.2 Hz, 1H), 6.76 (t, *J* = 9.5 Hz, 2H), 6.47 (d, *J* = 2.3 Hz, 1H), 6.44 (dd, *J* = 2.3, 8.6 Hz, 1H), 5.60 (d, *J* = 9.7 Hz, 1H), 4.75 (s, 2H), 3.82 (s, 3H), 3.79 (s, 3H), 3.67 (t, *J* = 7.5 Hz, 2H), 3.14 (t, *J* = 6.9 Hz, 2H), 1.43 (s, 6H); ¹⁶C-NMR (125 MHz, CDCl₃): δ 161.6, 160.4, 158.7, 147.0, 133.4, 130.4, 129.9, 128.3, 121.6, 119.7, 118.1, 116.8, 115.8, 113.4, 112.7, 104.3, 98.6, 75.2, 55.5, 47.5, 44.0, 27.4, 22.9 (two carbons are overlapped); HRMS (ESI): calcd for C₂:H₂:N₂O₄ [M+H]⁺ 419.1971, found 419.1973.



2-Bromo-9-(2,4-dimethoxybenzyl)-3,3-dimethyl-7,9,10,11-tetrahydropyrano[3,2-*e*]pyrido[3,4-*b*]indol-8(3*H*)-one (12)

58 mg, 12%: Colorless powder: mp 189—191 °C; IR (CHCl₃): 3207, 1636 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃): δ 9.98 (br s, 1H), 7.27 (d, *J* = 8.6 Hz, 1H), 7.19 (d, *J* = 8.6 Hz, 1H), 7.09 (s, 1H), 6.77 (d, *J* = 9.2 Hz, 1H), 6.48 (d, *J* = 2.3, Hz, 1H), 6.45 (dd, *J* = 2.6, 8.1 Hz, 1H), 4.75 (s, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.69 (t, *J* = 7.6 Hz, 2H), 3.14 (t, *J* = 1.6 Hz, 1H), 4.75 (s, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.69 (t, *J* = 7.6 Hz, 2H), 3.14 (t, *J* = 1.6 Hz, 1H), 4.75 (s, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.69 (t, *J* = 7.6 Hz, 2H), 3.14 (t, *J* = 1.6 Hz, 1H), 4.75 (s, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.69 (t, *J* = 7.6 Hz, 2H), 3.14 (t, *J* = 1.6 Hz, 1H), 4.75 (s, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.69 (t, J = 7.6 Hz, 2H), 3.14 (t, J = 1.6 Hz, 1H), 4.75 (s, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.69 (t, J = 7.6 Hz, 2H), 3.14 (t, J = 1.6 Hz, 1H), 4.75 (s, 2H), 3.82 (s, 3H), 3.80 (s, 3H), 3.69 (t, J = 7.6 Hz, 2H), 3.14 (t, J = 1.6 Hz, 1H), 4.75 (s, 2H), 3.81 (s, 3H), 3.80 (s, 3H), 3.69 (s, 3H), 3.69

7.4 Hz, 2H), 1.54 (s, 6H); ¹⁰C-NMR (125 MHz, CDCl₃): δ 161.4, 160.4, 158.7, 145.7, 133.6, 130.5, 128.6, 124.2, 123.2, 120.7, 118.0, 116.5, 115.6, 114.1, 113.2, 104.3, 98.6, 79.4, 55.5, 47.5, 44.1, 26.0, 22.7 (two carbons are overlapped); HRMS (ESI): calcd for C₂H₂BrN₂NaO₄ [M+Na]⁵ 519.0895, 521.0875, found 519.0896, 521.0876.



Trichloromethyl(2-(7,7-dimethyl-3,7-dihydropyrano[3,2-e]indol-1-yl)ethyl)(4-methoxybenzyl)carbamate(13b)

Triphosgene (312 mg, 1.05 mmol) was added to a mixture of **8b** (1 mmol) and Et₃N (0.35 mL, 2.5 mmol) in THF (40 mL) at room temperature and the mixture was stirring for 0.5 h. After addition of H₂O (20 mL), the whole was extracted with AcOEt (3 x 50 mL), washed with brine (2 x 30 mL). The organic layer was dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by silica gel column chromatography (AcOEt/hexane = 1/10) to give **13b** (460 mg, 88%) as a colorless powder.

460 mg, 88%: Colorless powder: mp 83—84 °C; IR (CHCl₃): 3477, 1722 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃): δ 7.87, 7.91 (2 br s, 1H), 7.08-7.14 (m, 3H), 6.92 (s, 1H), 6.82-6.89 (m, 3H), 6.73 (dd, *J* = 6.9, 8.6 Hz, 1H), 5.64 (d, *J* = 10.3 Hz, 1H), 4.49 (s, 1H), 4.36 (s, 1H), 3.77, 3.78 (2s, 3H), 3.64 (t, *J* = 8.0 Hz, 1H), 3.57 (t, *J* = 7.5 Hz, 1H), 3.13 (t, *J* = 8.0 Hz, 1H), 3.10 (t, *J* = 7.5 Hz, 1H), 1.45 (s, 3H), 1.43 (s, 3H); ¹⁶C-NMR (125 MHz, CDCl₃): δ 159.5, 159.5, 150.2, 149.3, 147.0, 146.9, 132.4, 130.2, 129.9, 128.8, 127.9, 127.5, 124.1, 124.0, 122.6, 122.5, 119.8, 119.9, 114.3, 114.2, 113.3, 113.2, 112.2, 112.0, 111.6, 111.4, 75.0, 55.4, 54.8, 52.6, 50.8, 50.5, 27.3, 26.4, 25.0 (rotamers were observed); HRMS (ESI): calcd for C₈H₈cl₁N₂O₄ [M+H]⁺ 523.0958, 525.0929, found 523.0953, 525.0925.

Procedure for the C2 Pictet-Spengler Reaction of 13b

A solution of compound **13b** (52 mg, 0.1 mmol) in DMSO was heated at 100 °C for 0.5 h. After removal of MeCN by evaporation, the resultant mixture was purified by silica gel column chromatography (AcOEt/hexane = 3/1-5:1) to give **9b** (33 mg, 86%) as a colorless powder.

General Procedure for the the Interrupted Phosgene Cyclization/Bischler-Napieralski-type Cyclization of 8

Triphosgene (312 mg, 1.05 mmol) was added to a mixture of **8** (1 mmol) and Et₃N (0.35 mL, 2.5 mmol) in THF (40 mL) was added at room temperature and the mixture was stirring for 0.5 h. After addition of H₂O (20 mL), the whole was extracted with AcOEt (3 x 50 mL), washed with brine (2 x 30 mL). The organic layer was dried over MgSO₄ and concentrated *in vacuo*. The crude residue was used without further purification. A solution of the crude in DMSO was heated at 100 °C for 0.5 h. After removal of MeCN by evaporation, the resultant mixture was purified by silica gel column chromatography (AcOEt/hexane = 3/1 - 5:1) to give **9**.

9a: 280 mg, 78%

9b: 253 mg, 65%



3,3-Dimethyl-7,9,10,11-tetrahydropyrano[3,2-*e*]pyrido[3,4-*b*]indol-8(3*H*)-one (10).

To a solution of compound **9c** (42 mg, 0.1 mmol) in toluene was *p*-toluenesulfonic acid (69 mg, 0.4 mmol) and heated at 100 °C for 16 h. After removal of toluene by evaporation, the resultant mixture was purified by silica gel column chromatography (AcOEt/hexane/CHCl/MeOH/28% NH₃ = 50/100/50/50/1) to give **10** (18 mg, 67%) as a colorless powder.

18 mg, 67%: Colorless powder: mp 149–150 °C; IR (CHCl₃): 3460, 3421, 3229, 1719, 1663 cm⁻¹; ¹H-NMR (500 MHz, CDCl₃): δ 9.09 (br s, 1H), 7.17 (d, *J* = 8.6 Hz, 1H), 6.84 (d, *J* = 9.2 Hz, 1H), 6.80 (d, *J* = 8.6 Hz, 1H), 5.73 (br s, 1H), 5.64 (d, *J* = 10.3 Hz, 1H), 3.69-3.71 (m, 2H), 3.21 (t, *J* = 6.9 Hz, 2H), 1.45 (s, 6H); ¹⁰C-NMR (125 MHz, CDCl₃): δ 163.0, 147.3, 133.0, 130.3, 127.2, 121.7, 119.5, 118.7, 116.6, 113.7, 112.5, 75.5, 42.2, 27.4, 23.0 (one carbon is overlapped); HRMS (ESI): calcd for C₁₆H₁₇N₂O₂ [M+H]⁺ 269.1290, found 269.1289.



fontanesine B

4,4-Dimethyl-4,7,8,16-tetrahydro-10*H*-pyrano[3'',2'':4',5']indolo[2',3':3,4]pyrido[2,1-*b*]quinazolin-10-one (Fontanesine B, 2).

To a solution of compound **10** (13 mg, 0.05 mmol) and anthranilic acid (8 mg, 0.06 mmol) in toluene was added POCL (18 mg, 0.12 mmol) at room temperature and the mixture was heated at 100 °C for 2 h. After removal of toluene by evaporation, the resultant mixture was purified by silica gel column chromatography (AcOEt/CHCL = 5/1) to give **2** (14 mg, 73%) as a pale yellow powder.

pale yellow powder; mp 261 – 263 °C; IR (CHCl₃): 3396, 1668, 1660 cm⁻¹; ¹H-NMR (500 MHz, DMSO- d_3): δ 11.71 (br s, 1H), 8.12 (d, J = 8.0 Hz, 1H), 7.77 (td, J = 1.2, 6.5 Hz, 1H), 7.64 (d, J = 8.1 Hz, 1H), 7.43 (td, J = 1.2, 7.4 Hz, 1H), 7.12 (s, 1H), 6.93 (s, 1H), 6.53 (d, J = 9.7 Hz, 1H), 5.81 (d, J = 9.8 Hz, 1H), 4.38 (t, J = 6.9 Hz, 2H), 3.06 (t, J = 7.5 Hz, 2H), 1.34 (s, 6H); ¹⁰C-NMR (125 MHz, DMSO- d_3): δ 161.1, 148.0, 146.8, 145.8, 135.0, 130.7, 128.5, 127.1, 127.0, 126.5, 121.5, 121.2, 119.8, 117.1, 116.1, 113.3, 113.2, 75.6, 41.1, 27.5, 21.3; HRMS (ESI): calcd for C₂₀H₂₀N₁O₂ [M+H]¹ 370.1556, found 370.1557.























